Epizyme Inc on Thursday priced its treatment for a ultra rare, slow growing type of cancer that affects soft tissue at $15,500 per month after getting an approval from the U.S. Food and Drug Administration.
from Reuters: Health News https://ift.tt/2TTIJfs
0 comments:
Post a Comment